Clinical Trial Update: Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor [Phase 3]

View source ↗

Summary

Phase 3 trial assessing omission of chemotherapy in HR-positive/HER2-negative, node-negative breast cancer patients receiving adjuvant endocrine therapy with a …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor
• Endocrine therapy

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING